In models where both EGFR and EZH2 are inhibited, the malignant progression of CRC is significantly suppressed, suggesting that the antiproliferative effects of EGFR inhibition may stem from decreased EZH2‐mediated histone methylation [168]. The gene discussed is EGFR; the disease is colorectal carcinoma.